Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine
William Montgomery,1 Zbigniew Kadziola,2 Wenye Ye,3 Hai Bo Xue,4 Li Liu,4 Tamás Treuer5 1Global Patient Outcomes and Real World Evidence, Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia; 2Real World Analytics Capabilities, Eli Lilly GmbH, Vienna, Austria; 3Real World Analytics, El...
Guardado en:
Autores principales: | , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9f31026778314d5795bd07a66b07871b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:9f31026778314d5795bd07a66b07871b |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:9f31026778314d5795bd07a66b07871b2021-12-02T08:08:55ZCorrelation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine1178-2021https://doaj.org/article/9f31026778314d5795bd07a66b07871b2015-01-01T00:00:00Zhttp://www.dovepress.com/correlation-between-changes-in-quality-of-life-and-symptomatic-improve-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021 William Montgomery,1 Zbigniew Kadziola,2 Wenye Ye,3 Hai Bo Xue,4 Li Liu,4 Tamás Treuer5 1Global Patient Outcomes and Real World Evidence, Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia; 2Real World Analytics Capabilities, Eli Lilly GmbH, Vienna, Austria; 3Real World Analytics, Eli Lilly and Company, Indianapolis, IN, USA; 4Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of China; 5Neuroscience Research, Eli Lilly and Company, Budapest, HungaryPurpose: The aim of this study was to investigate the correlation between changes in symptoms and changes in self-reported quality of life among Chinese patients with schizophrenia who were switched from a typical antipsychotic to olanzapine during usual outpatient care. Patients and methods: This post hoc analysis was conducted using data from the Chinese subgroup (n=475) of a multicountry, 12-month, prospective, noninterventional, observational study. The primary publication previously reported the efficacy, safety, and quality of life among patients who switched from a typical antipsychotic to olanzapine. Patients with schizophrenia were included if their symptoms were inadequately controlled with a typical antipsychotic and they were switched to olanzapine. Symptom severity was measured using the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impressions-Severity scale (CGI-S). Health-Related Quality of Life (HRQOL) was assessed using the World Health Organization Quality of Life–Abbreviated (WHOQOL-BREF). Paired t-tests were performed to assess changes from baseline to endpoint. Pearson’s correlation coefficients (r) were used to assess the correlations between change in symptoms (BPRS and CGI-S scores) and change in HRQOL (WHOQOL-BREF scores). Results: Symptoms and HRQOL both improved significantly over the 12 months of treatment (P<0.001). Significant correlations were observed between changes from baseline to end of study on the BPRS and the CGI-S and each of the WHOQOL-BREF four domain scores and two overall quality-of-life questions. The correlation coefficients ranged from r=−0.45 to r=−0.53 for the BPRS and WHOQOL-BREF. The correlation coefficients were slightly smaller between the CGI-S and WHOQOL-BREF, ranging from r=−0.33 to r=−0.40.Conclusion: For patients with schizophrenia, assessing quality of life has the potential to add valuable information to the clinical assessment that takes into account the patient’s own perspective of well-being. Keywords: data correlation, olanzapine, quality of life, schizophrenia, signs and symptomsMontgomery WKadziola ZYe WXue HBLiu LTreuer TDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 177-183 (2015) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Montgomery W Kadziola Z Ye W Xue HB Liu L Treuer T Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine |
description |
William Montgomery,1 Zbigniew Kadziola,2 Wenye Ye,3 Hai Bo Xue,4 Li Liu,4 Tamás Treuer5 1Global Patient Outcomes and Real World Evidence, Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia; 2Real World Analytics Capabilities, Eli Lilly GmbH, Vienna, Austria; 3Real World Analytics, Eli Lilly and Company, Indianapolis, IN, USA; 4Lilly Suzhou Pharmaceutical Company, Ltd, Shanghai, People’s Republic of China; 5Neuroscience Research, Eli Lilly and Company, Budapest, HungaryPurpose: The aim of this study was to investigate the correlation between changes in symptoms and changes in self-reported quality of life among Chinese patients with schizophrenia who were switched from a typical antipsychotic to olanzapine during usual outpatient care. Patients and methods: This post hoc analysis was conducted using data from the Chinese subgroup (n=475) of a multicountry, 12-month, prospective, noninterventional, observational study. The primary publication previously reported the efficacy, safety, and quality of life among patients who switched from a typical antipsychotic to olanzapine. Patients with schizophrenia were included if their symptoms were inadequately controlled with a typical antipsychotic and they were switched to olanzapine. Symptom severity was measured using the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impressions-Severity scale (CGI-S). Health-Related Quality of Life (HRQOL) was assessed using the World Health Organization Quality of Life–Abbreviated (WHOQOL-BREF). Paired t-tests were performed to assess changes from baseline to endpoint. Pearson’s correlation coefficients (r) were used to assess the correlations between change in symptoms (BPRS and CGI-S scores) and change in HRQOL (WHOQOL-BREF scores). Results: Symptoms and HRQOL both improved significantly over the 12 months of treatment (P<0.001). Significant correlations were observed between changes from baseline to end of study on the BPRS and the CGI-S and each of the WHOQOL-BREF four domain scores and two overall quality-of-life questions. The correlation coefficients ranged from r=−0.45 to r=−0.53 for the BPRS and WHOQOL-BREF. The correlation coefficients were slightly smaller between the CGI-S and WHOQOL-BREF, ranging from r=−0.33 to r=−0.40.Conclusion: For patients with schizophrenia, assessing quality of life has the potential to add valuable information to the clinical assessment that takes into account the patient’s own perspective of well-being. Keywords: data correlation, olanzapine, quality of life, schizophrenia, signs and symptoms |
format |
article |
author |
Montgomery W Kadziola Z Ye W Xue HB Liu L Treuer T |
author_facet |
Montgomery W Kadziola Z Ye W Xue HB Liu L Treuer T |
author_sort |
Montgomery W |
title |
Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine |
title_short |
Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine |
title_full |
Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine |
title_fullStr |
Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine |
title_full_unstemmed |
Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine |
title_sort |
correlation between changes in quality of life and symptomatic improvement in chinese patients switched from typical antipsychotics to olanzapine |
publisher |
Dove Medical Press |
publishDate |
2015 |
url |
https://doaj.org/article/9f31026778314d5795bd07a66b07871b |
work_keys_str_mv |
AT montgomeryw correlationbetweenchangesinqualityoflifeandsymptomaticimprovementinchinesepatientsswitchedfromtypicalantipsychoticstoolanzapine AT kadziolaz correlationbetweenchangesinqualityoflifeandsymptomaticimprovementinchinesepatientsswitchedfromtypicalantipsychoticstoolanzapine AT yew correlationbetweenchangesinqualityoflifeandsymptomaticimprovementinchinesepatientsswitchedfromtypicalantipsychoticstoolanzapine AT xuehb correlationbetweenchangesinqualityoflifeandsymptomaticimprovementinchinesepatientsswitchedfromtypicalantipsychoticstoolanzapine AT liul correlationbetweenchangesinqualityoflifeandsymptomaticimprovementinchinesepatientsswitchedfromtypicalantipsychoticstoolanzapine AT treuert correlationbetweenchangesinqualityoflifeandsymptomaticimprovementinchinesepatientsswitchedfromtypicalantipsychoticstoolanzapine |
_version_ |
1718398616912003072 |